IPO activity seems to have picked up in the U.S. with investors expecting the new Trump government to further its ...

A strong U.S. economy and lower interest rates could foster a surge in the number of initial public offerings in 2025, ...

At $23 a share — the new low end of Venture Global’s IPO price range — the company would be valued at about $56bn, on par ...

Expectations of a favorable business climate and less stringent regulations under the incoming Trump administration have made ...

The U.S. IPO market had a strong 2024 when compared with recent years, and when compared with the rest of the world.

The outlook for the Norwegian IPO market is unclear after a year with several departures and transfers from the Oslo Stock ...

It sold 70 million shares to raise $1.75 billion on Thursday, selling the stock at $25 compared to its offer price of $23 to ...

The IPO was expected to be the first blockbuster listing of 2025, as well as a litmus test for the appetite for energy ...

A global biopharma with a U.S. headquarters in Montgomery County is gearing up to go public on a U.S. exchange.

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...